| Cost-Effectiveness Analysis for Surgical, Angioplasty, or Medical Therapeutics for Coronary Artery Disease: 5-Year Follow-Up of Medicine, Angioplasty, or Surgery Study (MASS) II Trial. | |
| | |
MedLine Citation:
|
PMID: 22965975 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
BACKGROUND: The Second Medicine, Angioplasty, or Surgery Study (MASS II) included patients with multivessel coronary artery disease and normal systolic ventricular function. Patients underwent coronary artery bypass graft surgery (CABG, n=203), percutaneous coronary intervention (PCI, n=205), or medical treatment alone (MT, n=203). This investigation compares the economic outcome at 5-year follow-up of the 3 therapeutic strategies. METHODS AND RESULTS: We analyzed cumulative costs during a 5-year follow-up period. To analyze the cost-effectiveness, adjustment was made on the cumulative costs for average event-free time and angina-free proportion. Respectively, for event-free survival and event plus angina-free survival, MT presented 3.79 quality-adjusted life-years and 2.07 quality-adjusted life-years; PCI presented 3.59 and 2.77 quality-adjusted life-years; and CABG demonstrated 4.4 and 2.81 quality-adjusted life-years. The event-free costs were $9071.00 for MT; $19 967.00 for PCI; and $18 263.00 for CABG. The paired comparison of the event-free costs showed that there was a significant difference favoring MT versus PCI (P<0.01) and versus CABG (P<0.01) and CABG versus PCI (P=0.01). The event-free plus angina-free costs were $16 553.00, $25 831.00, and $24 614.00, respectively. The paired comparison of the event-free plus angina-free costs showed that there was a significant difference favoring MT versus PCI (P=0.04), and versus CABG (P<0.001); there was no difference between CABG and PCI (P>0.05). CONCLUSIONS: In the long-term economic analysis, for the prevention of a composite primary end point, MT was more cost effective than CABG, and CABG was more cost-effective than PCI. CLINICAL TRIAL REGISTRATION INFORMATION: www.controlled-trials.com. Registration number: ISRCTN66068876. |
| | |
Authors:
|
Ricardo D'Oliveira Vieira; Whady Hueb; Mark Hlatky; Desiderio Favarato; Paulo Cury Rezende; Cibele Larrosa Garzillo; Eduardo Gomes Lima; Paulo Rogério Soares; Alexandre Ciappina Hueb; Alexandre Costa Pereira; José Antonio Franchini Ramires; Roberto Kalil Filho |
Related Documents
:
|
7603485 - Myocardial ischemia and reperfusion. 21087715 - A new monocyte chemotactic protein-1/chemokine cc motif ligand-2 competitor limiting ne... 23642815 - Effects of the novel angiotensin ii receptor type i antagonist, fimasartan on myocardia... 12235245 - Postischemic recovery and oxidative stress are independent of nitric-oxide synthases mo... 17652805 - Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. 2786015 - St segment shift in unstable angina: pathophysiology and association with coronary anat... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Circulation Volume: 126 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2012 Sep |
Date Detail:
|
Created Date: 2012-09-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: S145-50 Citation Subset: AIM; IM |
Affiliation:
|
Heart Institute of the University of São Paulo, Eneas Carvalho Aguiar 44 AB 114, São Paulo, Brazil. whady.hueb@incor.usp.br. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Radial artery free and T graft patency as coronary artery bypass conduit over a 15-year period.
Next Document: Benefits of off-pump coronary artery bypass grafting in high-risk patients.